151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CytomX Therapeutics Approves 2015 Plan Amendment for 6.5M Shares
Amendment No. 4 to Collaboration Agreement with Regeneron Executed
Announces Q1 2026 Financial Results and Provides Business Update
CytomX Therapeutics Enters Underwriting Agreement for 45.99M Shares
Announces 2025 Financial Results and Provides Business Update
Announces Third Quarter 2025 Financial Results and Provides Business Update
Other Events
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload